Lv6
1670 积分 2022-11-11 加入
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2天前
已完结
MASLD, MASH, and the CKM Spectrum
3天前
求助中
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
3天前
已完结
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
4天前
已完结
Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications
6天前
已完结
Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice
6天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease and Metabolic Dysfunction–Associated Steatohepatitis–Related Fibrosis: Therapeutic Options and Approaches to Treatment
6天前
已完结
Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia
6天前
已完结
A new treatment and updated clinical practice guidelines for MASLD
11天前
已完结
Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH
11天前
已完结
皖公网安备34019202002308
